Target type: biologicalprocess
The chemical reactions and pathways involving diacylglycerol, a glyceride in which any two of the R groups (positions not specified) are acyl groups while the remaining R group can be either H or an alkyl group. [PMID:11481335]
Diacylglycerol (DAG) metabolic process is a critical pathway in cellular signaling and lipid metabolism. DAG is a lipid molecule that serves as a key intermediate in the synthesis of various important lipids, including phospholipids, triacylglycerols, and phosphoinositides. It is also a potent signaling molecule, activating protein kinase C (PKC), a family of enzymes that regulate a wide range of cellular functions.
The metabolic process of DAG begins with the hydrolysis of phospholipids, particularly phosphatidylinositol 4,5-bisphosphate (PIP2), by phospholipase C (PLC). This reaction produces DAG and inositol 1,4,5-trisphosphate (IP3), both of which are important second messengers in cellular signaling.
DAG can be further metabolized in several ways. It can be incorporated into phospholipids via the CDP-diacylglycerol pathway, which involves the synthesis of phosphatidic acid (PA) and subsequent conversion to various phospholipids. DAG can also be acylated to form triacylglycerols (TAG), the main storage form of fat in the body. Alternatively, DAG can be phosphorylated by DAG kinase to produce phosphatidic acid (PA).
DAG signaling plays a crucial role in numerous cellular processes, including:
* **Cell growth and differentiation:** DAG activates PKC, which is involved in various signaling cascades regulating cell growth, proliferation, and differentiation.
* **Cellular motility and migration:** DAG signaling influences actin cytoskeletal dynamics, which is essential for cell motility and migration.
* **Insulin signaling:** DAG is involved in the insulin signaling pathway, regulating glucose uptake and metabolism.
* **Calcium signaling:** DAG interacts with calcium signaling pathways, contributing to the regulation of various cellular processes.
* **Immune responses:** DAG signaling modulates the activity of immune cells, contributing to immune responses.
Disruptions in DAG metabolism can lead to various diseases, including cancer, diabetes, and neurodegenerative diseases. Therefore, understanding the intricate mechanisms of DAG metabolic processes is essential for developing novel therapeutic strategies targeting these diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Diacylglycerol O-acyltransferase 2 | A diacylglycerol O-acyltransferase 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q96PD7] | Homo sapiens (human) |
Diacylglycerol kinase alpha | A diacylglycerol kinase alpha that is encoded in the genome of human. [PRO:DNx, UniProtKB:P23743] | Homo sapiens (human) |
Diacylglycerol O-acyltransferase 1 | A diacylglycerol O-acyltransferase 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O75907] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
r 59022 | R 59022: diacylglycerol kinase inhibitor; structure given in first source; platelet activator factor antagonist | diarylmethane | |
dioctanoyl ethylene glycol | |||
ritanserin | ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action. Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure. | organofluorine compound; piperidines; thiazolopyrimidine | antidepressant; antipsychotic agent; anxiolytic drug; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist |
cochlioquinone a | cochlioquinone A: from Helminthosporium sativum; competitive inhibitor of ivermectin binding; RN from Chem Abstract Index Guide 1990; structure given in first source | oxanes | |
r 59949 | R 59949: diacylglycerol kinase inhibitor | diarylmethane | |
1-monooleoyl-rac-glycerol | 1-oleoylglycerol : A 1-monoglyceride where the acyl group is oleoyl. monooleoylglycerol : A monoglyceride in which the acyl group is oleoyl with the position of acylation unspecified. Peceol: lipid excipient containing readily dispersible mixture of mono- & diglycerides of oleic acid | 1-acylglycerol 18:1; monooleoylglycerol | plant metabolite |
stemphone | stemphone: structure given in first source | ||
azd3988 | AZD3988: for treatment of obesity and diabetes; structure in first source | ||
a-922500 | aromatic ketone | ||
azd7687 | AZD7687: structure in first source | ||
pf-04620110 | PF-04620110: a DGAT1 inhibitor; structure in first source | ||
pradigastat | |||
pf-06424439 | PF-06424439: an inhibitor of diacylglycerol acyltransferase 2; structure in first source |